FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2328-2330 November 25, 2004 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Perspective by Steinbrook, R. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Laughlin, M. J. Related Article by Rocha, V. PubMed Citation

A steady stream of advances in allogeneic hematopoietic stem-cell transplantation has not only improved the clinical outcome in a variety of malignant and nonmalignant diseases but also widened the indications for such transplants. One important advance is the use of sources of hematopoietic stem cells other than bone marrow from HLA-identical siblings, which is a resource available to only about 30 percent of potential recipients.

By searching international databases, which contain more than 9 million potential volunteer stem-cell donors,¹ a matched unrelated donor can be found for an additional 50 to 80 percent of patients, depending on ethnic group. In . . . [Full Text of this Article]

Source Information

From the Hematology Department, Hospital Universitario La Fe, 46009 Valencia, Spain.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.